Diabetes Drug Tirzepatide Shows Promise in Curbing Alcohol Addiction

A diabetes medication called tirzepatide, marketed as Mounjaro, is demonstrating potential as a novel treatment for alcohol dependence. Recent human trials have yielded promising results, with two completed studies reporting reduced drinking in participants. Researchers believe the drug could offer a new approach to combating addiction by gradually altering brain function.

The drug, already authorized for diabetes, has been tested in two Phase 2 clinical trials. The first, conducted in the USA and concluded in December 2024, found that tirzepatide decreased the number of heavy drinking days. A second trial in Denmark, completed in January 2026, showed similar effects, with participants drinking less overall.

Earlier animal studies at the University of Gothenburg initially indicated the drug's potential. Rats given tirzepatide consumed over 50% less alcohol and were less likely to relapse. Unlike existing treatments, tirzepatide targets two key receptors—GIP and GLP-1—which may give it a stronger impact on addictive behavior. It also appears to dampen the brain's dopamine response to alcohol, reducing cravings.

Scientists have observed that the drug might induce lasting biological changes in the brain, including epigenetic modifications. These could help sustainably alter addictive patterns. However, no Phase 3 trials have begun yet, and further testing is required before approval for alcohol use disorder.

Tirzepatide's existing approval for diabetes could expedite its regulatory review for addiction treatment. If successful, it may provide a much-needed alternative to current therapies. For now, researchers are planning additional studies to confirm its safety and effectiveness in larger groups.